INVIVYD INC (IVVD)
Health Care · Monoclonal antibody therapeutics / viral infectious diseases · NASDAQ
Invivyd develops monoclonal antibody therapeutics for serious viral infections, with PEMGARDA approved for COVID-19 emergency use and a pipeline targeting RSV, measles, and other evolving pathogens.
What INVIVYD INC does
Invivyd Inc is a clinical-stage biopharmaceutical company focused on developing monoclonal antibodies (mAbs) for the prevention and treatment of serious viral infectious diseases, particularly COVID-19. The company commercializes PEMGARDA® (pemivibart), which received FDA emergency use authorization in March 2024, and is advancing VYD2311, a next-generation mAb candidate for COVID-19, through its REVOLUTION clinical program. The company is building a pipeline targeting additional high-need indications including respiratory syncytial virus (RSV) and measles, with a focus on delivering differentiated, rapidly updatable therapeutics as viral pathogens evolve.
Themes: ["COVID-19 therapeutics / monoclonal antibodies","Respiratory viral infections (RSV)","Monoclonal antibody development","Emergency infectious disease response","Viral evolution countermeasures"]
Fundamentals
- Price$0.80 as of 2026-07-09 close
- Market cap$237M as of 2026-07-10
- 1-year return+15.2% as of 2026-07-09 close
- Net margin-138.9% as of 2026-07-10
- Gross margin+92.9% as of 2026-07-10
- ROE-53.5% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+52.3% as of 2026-07-10
- Beta0.74 as of 2026-07-10
Key risks (from latest filing)
["Company is unprofitable with negative net margin of -138.9% and substantial accumulated deficit of $995.9 million, requiring continued funding to support operations and clinical development programs","Dependence on continued FDA authorization and market adoption of PEMGARDA, which received only emergency use authorization (not full approval) and faces competitive pressures from other COVID-19 therapeutics","Reliance on third parties for clinical trials, manufacturing, and testing; any delays or failures in these partnerships could adversely impact development timelines and commercialization of product candidates"]
Competitors & peers
- Eli Lilly (LLY)
- Regeneron Pharmaceuticals (REGN)
- Genmab A/S
- Roche/Genentech
- GSK (GlaxoSmithKline)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.